Interleukin (IL)-6 inhibits IL-27- and IL-30-mediated inflammatory responses in human monocytes

Frontiers in Immunology

Volumn 9, Issue FEB, 2018, Pages

  Petes, Carlene ^a   Mariani, Mélissa K ^b   Yang, Yawen ^a   Grandvaux, Nathalie ^b   Gee, Katrina ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Human CD4 T cells; Human monocytes; Inflammation; Interleukin 27; Interleukin 30

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 130; INTERLEUKIN 27; INTERLEUKIN 30; INTERLEUKIN 6; STAT PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; MONOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 85042066811     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00256     Document Type: Article

References (44)

1. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 16(6):779-90. doi:10.1016/S1074-7613(02)00324-2
2. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol (2004) 172(4):2225-31. doi:10.4049/jimmunol.172.4.2225
3. Crabé S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, Guilhot F, et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J Immunol (2009) 183(12):7692-702. doi:10.4049/jimmunol.0901464
4. Shimozato O, Sato A, Kawamura K, Chiyo M, Ma G, Li Q, et al. The secreted form of p28 subunit of interleukin (IL)-27 inhibits biological functions of IL-27 and suppresses anti-allogeneic immune responses. Immunology (2009) 128(1pt2):e816-25. doi:10.1111/j.1365-2567.2009.03088.x
5. Stumhofer JS, Tait ED, Quinn WJ III, Hosken N, Spudy B, Goenka R, et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 11(12):1119-26. doi:10.1038/ni.1957
6. Dibra D, Cutrera JJ, Li S. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30. J Immunol (2012) 188(8):3709-15. doi:10.4049/jimmunol.1100883
7. Blahoianu MA, Rahimi AA, Kozlowski M, Angel JB, Kumar A. IFN-γ-induced IL-27 and IL-27p28 expression are differentially regulated through JNK MAPK and PI3K pathways independent of Jak/STAT in human monocytic cells. Immunobiology (2014) 219(1):1-8. doi:10.1016/j.imbio.2013.06.001
8. Guzzo C, Mat NFC, Gee K. Interleukin-27 induces a STAT1/3-and NF-κB-dependent proinflammatory cytokine profile in human monocytes. J Biol Chem (2010) 285(32):24404-11. doi:10.1074/jbc.M110.112599
9. Villarino AV, Huang E, Hunter CA. Understanding the pro-and anti-inflammatory properties of IL-27. J Immunol (2004) 173(2):715-20. doi:10.4049/jimmunol.173.2.715
10. Yoshida H, Hamano S, Miyazaki Y. The double identity of WSX-1 (IL-27R) as an initiator and an attenuator of immune responses. Curr Immunol Rev (2005) 1(1):55-60. doi:10.2174/1573395052952923
11. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Hölscher C, et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem (2013) 288(6):4346-54. doi:10.1074/jbc.M112.432955
12. Guzzo C, Ayer A, Basta S, Banfield BW, Gee K. IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J Immunol (2012) 188(2):864-73. doi:10.4049/jimmunol.1101912
13. Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology (2012) 55(4):1204-14. doi:10.1002/hep.24814
14. Robitaille AC, Mariani MK, Fortin A, Grandvaux N. A high resolution method to monitor phosphorylation-dependent activation of IRF3. J Visual Exp (2016) 107:e53723. doi:10.3791/53723
15. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 13(11):1235-42. doi:10.1016/j.chembiol.2006.09.018
16. Szelag M, Sikorski K, Czerwoniec A, Szatkowska K, Wesoly J, Bluyssen HA. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. Eur J Pharmacol (2013) 720(1):38-48. doi:10.1016/j.ejphar.2013.10.055
17. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 334( Pt 2):297-314. doi:10.1042/bj3340297
18. Xia S, Wei J, Wang J, Sun H, Zheng W, Li Y, et al. A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells. J Leukoc Biol (2014) 95(5):733-42. doi:10.1189/jlb.0713371
19. Morandi F, Airoldi I, Pistoia V. IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-gamma release by autologous NK cells. J Immunol Res (2014) 2014:938561. doi:10.1155/2014/938561
20. Chong WP, Horai R, Mattapallil MJ, Silver PB, Chen J, Zhou R, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun (2014) 50:12-22. doi:10.1016/j.jaut.2013.08.003
21. Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget (2015) 6(41):43267. doi:10.18632/oncotarget.6530
22. Chang H-C, Kaiser CM, Hartl FU, Barral JM. De novo folding of GFP fusion proteins: high efficiency in eukaryotes but not in bacteria. J Mol Biol (2005) 353(2):397-409. doi:10.1016/j.jmb.2005.08.052
23. Pédelacq J-D, Cabantous S, Tran T, Terwilliger TC, Waldo GS. Engineering and characterization of a superfolder green fluorescent protein. Nat Biotechnol (2006) 24(1):79-88. doi:10.1038/nbt1172
24. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol (2003) 170(10):4886-90. doi:10.4049/jimmunol.170.10.4886
25. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and-independent mechanisms. Proc Natl Acad Sci U S A (2003) 100(25):15047-52. doi:10.1073/pnas.2536517100
26. Hibbert L, Pflanz S, de Waal Malefyt R, Kastelein RA. IL-27 and IFN-a signal via Stat1 and Stat3 and induce T-Bet and IL-12R β 2 in naive T cells. J Interferon Cytokine Res (2003) 23(9):513-22. doi:10.1089/10799900360708632
27. Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, Yoshimoto T. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol (2004) 173(6):3871-7. doi:10.4049/jimmunol.173.6.3871
28. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 8(12):1363-71. doi:10.1038/ni1537
29. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol (2008) 180(9):6325-33. doi:10.4049/jimmunol.180.9.6325
30. Owaki T, Asakawa M, Morishima N, Mizoguchi I, Fukai F, Takeda K, et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol (2008) 180(5):2903-11. doi:10.4049/jimmunol.180.5.2903
31. Diegelmann J, Olszak T, Göke B, Blumberg RS, Brand S. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J Biol Chem (2012) 287(1):286-98. doi:10.1074/jbc.M111.294355
32. Notredame C, Higgins DG, Heringa J. T-coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol (2000) 302(1):205-17. doi:10.1006/jmbi.2000.4042
33. Gorshkova E, Nedospasov S, Shilov E. Evolutionary plasticity of IL-6 cytokine family. Mol Biol (2016) 50(6):1039-48. doi:10.1134/S0026893316060066
34. Boulanger MJ, Chow D-C, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 a-receptor/gp130 complex. Science (2003) 300(5628):2101-4. doi:10.1126/science.1083901
35. Kalai M, Montero-Julian FA, Görtzinger J, Fontaine V, Vandenbussche P, Deschuyteneer R, et al. Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction. Blood (1997) 89(4):1319-33
36. Rousseau F, Basset L, Froger J, Dinguirard N, Chevalier S, Gascan H. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. Proc Natl Acad Sci U S A (2010) 107(45):19420-5. doi:10.1073/pnas.1005793107
37. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 8(9):1237. doi:10.7150/ijbs.4989
38. Arnold P, Boll I, Rothaug M, Schumacher N, Schmidt F, Wichert R, et al. Meprin metalloproteases generate biologically active soluble interleukin-6 receptor to induce trans-signaling. Sci Rep (2017) 7:44053. doi:10.1038/srep44053
39. Aparicio-Siegmund S, Deseke M, Lickert A, Garbers C. Trans-signaling of interleukin-6 (IL-6) is mediated by the soluble IL-6 receptor, but not by soluble CD5. Biochem Biophys Res Commun (2017) 484(4):808-12. doi:10.1016/j.bbrc.2017.01.174
40. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood (1993) 82(4):1120-6
41. Jostock T, Müllberg J, özbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. FEBS J (2001) 268(1):160-7. doi:10.1046/j.1432-1327.2001.01867.x
42. Morieri ML, Passaro A, Zuliani G. Interleukin-6 "trans-signaling" and ischemic vascular disease: the important role of soluble gp130. Mediators Inflamm (2017) 2017:1396398. doi:10.1155/2017/1396398
43. Hargreaves PG, Wang F, Antcliff J, Murphy G, Lawry J, Russell RGG, et al. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol (1998) 101(4):694-702. doi:10.1046/j.1365-2141.1998.00754.x
44. Scheller J, Schuster B, Hölscher C, Yoshimoto T, Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun (2005) 326(4):724-8. doi:10.1016/j.bbrc.2004.11.098